Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Brouwer, Philip J. M., Caniels, Tom G., van der Straten, Karlijn, Snitselaar, Jonne L., Aldon, Yoann, Bangaru, Sandhya, Torres, Jonathan L., Okba, Nisreen M. A., Claireaux, Mathieu, Kerster, Gius, Bentlage, Arthur E. H., van Haaren, Marlies M., Guerra, Denise, Burger, Judith A., Schermer, Edith E., Verheul, Kirsten D., van der Velde, Niels, van der Kooi, Alex, van Schooten, Jelle, van Breemen, Mariëlle J., Bijl, Tom P. L., Sliepen, Kwinten, Aartse, Aafke, Derking, Ronald, Bontjer, Ilja, Kootstra, Neeltje A., Wiersinga, W. Joost, Vidarsson, Gestur, Haagmans, Bart L., Ward, Andrew B., de Bree, Godelieve J., Sanders, Rogier W., van Gils, Marit J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299281/
https://www.ncbi.nlm.nih.gov/pubmed/32540902
http://dx.doi.org/10.1126/science.abc5902
Descripción
Sumario:The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.

Ejemplares similares